Excalibur Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.29M Buy
1,408
+66
+5% +$66.9K 0.46% 63
2025
Q4
$1.44M Sell
1,342
-55
-4% -$52.6K 0.52% 56
2025
Q3
$1.07M Sell
1,397
-21
-1% -$15.6K 0.39% 69
2025
Q2
$1.11M Sell
1,418
-50
-3% -$38.9K 0.41% 68
2025
Q1
$1.21M Buy
1,468
+2
+0.1% +$1.66K 0.48% 61
2024
Q4
$1.13M Buy
1,466
+88
+6% +$72.9K 0.45% 64
2024
Q3
$1.22M Buy
1,378
+6
+0.4% +$5.39K 0.47% 62
2024
Q2
$1.24M Buy
1,372
+83
+6% +$66.4K 0.51% 53
2024
Q1
$1M Hold
1,289
0.42% 64
2023
Q4
$751K Hold
1,289
0.35% 74
2023
Q3
$692K Buy
1,289
+18
+1% +$9.28K 0.36% 73
2023
Q2
$596K Buy
1,271
+9
+0.7% +$3.77K 0.3% 81
2023
Q1
$433K Hold
1,262
0.22% 98
2022
Q4
$462K Hold
1,262
0.24% 95
2022
Q3
$408K Hold
1,262
0.23% 92
2022
Q2
$409K Buy
1,262
+1
+0.1% +$300 0.21% 102
2022
Q1
$361K Hold
1,261
0.16% 115
2021
Q4
$348K Hold
1,261
0.14% 121
2021
Q3
$291K Hold
1,261
0.13% 133
2021
Q2
$289K Buy
1,261
+11
+0.9% +$2.21K 0.13% 133
2021
Q1
$234K Hold
1,250
0.12% 139
2020
Q4
$211K Buy
+1,250
New +$187K 0.11% 139
2020
Q3
Sell
-1,250
Closed -$205K 144
2020
Q2
$205K Buy
+1,250
New +$192K 0.14% 110

Other funds holding LLY

Excalibur Management's LLY Position: Q1 2026 in Review

Excalibur Management increased its Eli Lilly (LLY) stake by 4.9% in Q1 2026, buying an estimated $66.9K and bringing the position to 1,408 shares worth $1.29M. The position accounts for 0.46% of the portfolio, ranked #63.

Excalibur Management first reported a position in LLY in Q2 2020 and has held it in 23 quarters since. The position peaked at $1.44M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Excalibur Management held 1,408 shares of Eli Lilly worth $1.29M as of Q1 2026.
  • Excalibur Management bought 66 Eli Lilly shares in Q1 2026, an estimated $66.9K.
  • Eli Lilly made up 0.46% of Excalibur Management's portfolio in Q1 2026, its #63 holding.
  • Excalibur Management first reported a position in Eli Lilly in Q2 2020 and has held it in 23 quarters since.
  • Excalibur Management's Eli Lilly position peaked at $1.44M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Excalibur Management's 13F filing for Q1 2026, filed 5 May 2026.